ArticleHaematologica2021
The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy.
Abstract read
In one paragraph
Article in Haematologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Cytogenetic and Molecular Analysis of a "Double-Hit" RUNX1 Including a RUNX1 p.Trp279* and a Cryptic Novel t(6;21)(q25;q22)/RUNX1::ARID1B in Acute Myeloid Leukemia.Genes, chromosomes & cancer · 2026Article
- Timing is everything: age-dependent cancer risk in RUNX1-FPD.Blood advances · 2026Article
- Hematologic malignancies in pediatric patients with RUNX1-familial platelet disorder with associated myeloid malignancy.Blood advances · 2026Observational
- A new c.681dup RUNX1 variant in familial leukemia.Familial cancer · 2026Article
- Moving Beyond Somatic Alterations: Uncovering the Germline Basis of Myeloid Malignancies.Cancers · 2026Review
- Targeting RUNX1 Germline Variants: Agents Under Investigation.Current hematologic malignancy reports · 2025Review
- A Novel Approach to Prognostic Factors and Risk Stratification in Pediatric AML: Case Report and Literature Review.International journal of molecular sciences · 2025Review
- Article
- Germline and somatic genetic landscape of pediatric myelodysplastic syndromes.Haematologica · 2025Review
- Hereditary Hematopoietic Malignancies: Considerations for Optimizing Diagnosis and Management.Current oncology reports · 2025Review
- Dual mechanism of inflammation sensing by the hematopoietic progenitor genome.Science advances · 2025Article
- Genome sequencing in the management of myelodysplastic syndromes and related disorders.Haematologica · 2025Review
- Article
- RUNX1-FPDMM in families with mild thrombocytopenia and platelet function anomalies: a case series.Frontiers in medicine · 2025Article
- Review
- RUNX1 C-terminal mutations impair blood cell differentiation by perturbing specific enhancer-promoter networks.Blood advances · 2024Article
- Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome.International journal of molecular sciences · 2024Review
- Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41.Blood advances · 2023Article
- An Old Dog Has a New Trick: Somatic Exonic Deletions in RUNX1 Are Frequent in AML.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- RUNX1 is required in granulocyte-monocyte progenitors to attenuate inflammatory cytokine production by neutrophils.Genes & development · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
43 authors.
Claire C HomanDepartment of Genetics and Molecular Pathology, SA Pathology, Adelaide, SA, Australia; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA.
Sarah L King-SmithDepartment of Genetics and Molecular Pathology, SA Pathology, Adelaide, SA, Australia; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA.
David M LawrenceDepartment of Genetics and Molecular Pathology, SA Pathology, Adelaide, SA, Australia; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia; Australian Cancer Research Foundation (ACRF) Cancer Genomics Facility, Centre for Cancer Biology, SA Pathology, Adelaide, SA.
Peer ArtsDepartment of Genetics and Molecular Pathology, SA Pathology, Adelaide, SA, Australia; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA.
Jinghua FengCentre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia; Australian Cancer Research Foundation (ACRF) Cancer Genomics Facility, Centre for Cancer Biology, SA Pathology, Adelaide, SA.
James AndrewsDepartment of Genetics and Molecular Pathology, SA Pathology, Adelaide, SA, Australia; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA.
Mark ArmstrongDepartment of Genetics and Molecular Pathology, SA Pathology, Adelaide, SA, Australia; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA.
Thuong HaDepartment of Genetics and Molecular Pathology, SA Pathology, Adelaide, SA, Australia; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA.
Julia DobbinsDepartment of Genetics and Molecular Pathology, SA Pathology, Adelaide, SA, Australia; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA.
Michael W DrazerSection of Hematology/Oncology, Departments of Medicine and Human Genetics, Center for Clinical Cancer Genetics, and The University of Chicago Comprehensive Cancer Center, The University of Chicago, Chicago, IL.
Kai YuNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892.
Csaba BödörHCEMM-SE Molecular Oncohematology Research Group, 1st Department of P athology and E xperimental Cancer R esearch, Semmelweis U niversity, B udapest, H ungary.
Alan CantorDivision of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115.
Mario CazzolaDepartment of Molecular Medicine, University of Pavia, Pavia, Italy; Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia.
Erin DegelmanDivision of Hematology and Hematological Malignancies, Foothills Medical Centre, Calgary, AB.
Courtney D DiNardoDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
Nicolas DuployezLaboratory of Hematology, Biology and Pathology Center, Centre Hospitalier Regional Universitaire de Lille, Lille, France; Jean-Pierre Aubert Research Center, INSERM, Universitaire de Lille, Lille.
Remi FavierAssistance Publique- Hôpitaux de Paris, Armand Trousseau children's Hospital, Paris.
Stefan FröhlingDepartment of Translational Medical Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany.
Jude FitzgibbonCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London.
Jeffery M KlcoSt Jude Children's Research Hospital, Memphis, Tennessee, United States.
Alwin KrämerClinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Dept. of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Mineo KurokawaDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Japan.
Joanne LeeDepartment of Haematology-Oncology, National University Cancer Institute, National University Health System.
Luca MalcovatiDepartment of Molecular Medicine, University of Pavia, Pavia, Italy; Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia.
Neil V MorganInstitute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham.
Georges NatsoulisImago Biosciences, Inc., San Francisco, CA.
Carolyn OwenDivision of Hematology and Hematological Malignancies, Foothills Medical Centre, Calgary, AB.
Keyur P PatelDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
Claude PreudhommeLaboratory of Hematology, Biology and Pathology Center, Centre Hospitalier Regional Universitaire de Lille, Lille, France; Jean-Pierre Aubert Research Center, INSERM, Universitaire de Lille, Lille.
Hana RaslovaInstitut Gustave Roussy, Université Paris Sud, Equipe Labellisée par la Ligue Nationale Contre le Cancer, Villejuif.
Hugh RienhoffImago Biosciences, Inc., San Francisco, CA.
Tim RippergerDepartment of Human Genetics, Hannover Medical School, Hannover, Germany.
Rachael SchulteDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, Monroe Carell Jr. Children's Hospital, Vanderbilt University Medical Center, Nashville, TN.
Kiran TawanaDepartment of Haematology, Addenbrooke's Hospital. Cambridge, CB2 0QQ.
Elvira VellosoService of Hematology, Transfusion and Cell Therapy and Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31) HCFMUSP, University of Sao Paulo Medical School, Sao Paulo, Brazil; Genetics Laboratory, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
Benedict YanDepartment of Haematology-Oncology, National University Cancer Institute, National University Health System.
Paul LiuNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892.
Lucy A GodleySection of Hematology/Oncology, Departments of Medicine and Human Genetics, Center for Clinical Cancer Genetics, and The University of Chicago Comprehensive Cancer Center, The University of Chicago, Chicago, IL.
Andreas W SchreiberCentre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia; Australian Cancer Research Foundation (ACRF) Cancer Genomics Facility, Centre for Cancer Biology, SA Pathology, Adelaide, SA, Australia; School of Biological Sciences, University of Adelaide, Adelaide, SA.
Christopher N HahnDepartment of Genetics and Molecular Pathology, SA Pathology, Adelaide, SA, Australia; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia; School of Medicine, University of Adelaide, Adelaide, SA.
Hamish S ScottDepartment of Genetics and Molecular Pathology, SA Pathology, Adelaide, SA, Australia; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia; School of Biological Sciences, University of Adelaide, Adelaide, SA, Australia; School of Medicine, University of Adelaide, Adelaide, SA.
Anna L BrownDepartment of Genetics and Molecular Pathology, SA Pathology, Adelaide, SA, Australia; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia; School of Medicine, University of Adelaide, Adelaide, SA. anna.brown@sa.gov.au.
Funding
GENETIC ANALYSIS OF ZEBRAFISH EMBRYO DEVELOPMENTZIAHG000102 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI LIU, PAUL · 2009 to 2025
$17.1MMOLECULAR PATHOGENESIS OF CHROMOSOME 16 INVERSION INHUMAN LEUKEMIAZIAHG000030 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI LIU, PAUL · 2009 to 2025
$15.8MBiology and novel therapy of AML expressing somatic or germline mutant RUNX1R01CA255721 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BHALLA, KAPIL, DINARDO, COURTNEY · 2021 to 2025
$2.4MCancer Research UK 24375Medical Research Council G0700052NCI NIH HHS R01 CA255721
Abstract
PubMed holds no abstract for this paper.
Indexed as
Blood Platelet DisordersLeukemia, Myeloid, AcuteNeoplasmsCore Binding Factor Alpha 2 SubunitGenomicsHumansRegistriesCore Binding Factor Alpha 2 SubunitRUNX1 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.